Navigation Links
Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
Date:9/4/2013

these add months to the timeline. Our commitment to patient engagement, transparency and advocacy removes much of this wait time – accelerating the research and increasing the efficiency of the process overall."

Sanguine is able to meet, review disclosures and collect blood samples in a patient's home with its own phlebotomists in multiple major U.S. cities. Patients are also able to track how their de-identified biospecimen and data are used through the donor web portal. The company is able to collect and process blood from patients with any disease and has already built large libraries in multiple chronic and severe conditions, including Huntington's disease, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis and others.

In order to maintain appropriate confidentiality, all samples are de-identified immediately upon collection. Sanguine maintains and reviews internal ethical guidelines for the procedures under high scrutiny from an independent review board.

About Sanguine

Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers developing personalized medicine. The company engages patients in biomedical research by delivering transparency throughout the research process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen, and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery with leading academic laboratories and companies, such as Vertex Pharmaceuticals. (http://sanguinebio.com)

Media Contact:
Ian Stone
Russo Partners
Tel: +1 619-308-6541
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Sanguine BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
2. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
3. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
4. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
5. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
6. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
8. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
9. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
10. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
11. Neurocrine Biosciences Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form ... of special anti-vascular endothelial growth factor agents given by injection into the eye. ... have a scientific protocol for the many millions diagnosed with it. AMD usually ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug ... plant-derived compounds. BCC Research reveals in its new report that the U.S. ... defines the category and generates the most market demand. , BCC Research ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry ... their entire waste to energy process and continue to contribute to the sustainability ... , Temarry’s Waste to Energy process has been operating at their Mexico facility, ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... 13 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... Savient Pharmaceuticals,will present a corporate update at the upcoming ... is scheduled to begin on Tuesday, November 18, 2008 ... the St. Regis Hotel in New,York City November 18-19, ...
... Held Friday, November 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged ...
... ILI ) today announced financial and business results ... Company reported a net loss of $1.6 million, or ... quarter of 2008 compared to a net,loss of $1.1 ... for the,same period last year., "Collaborations are an ...
Cached Biology Technology:Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Interleukin Genetics Reports Third Quarter 2008 Financial Results 2Interleukin Genetics Reports Third Quarter 2008 Financial Results 3Interleukin Genetics Reports Third Quarter 2008 Financial Results 4Interleukin Genetics Reports Third Quarter 2008 Financial Results 5Interleukin Genetics Reports Third Quarter 2008 Financial Results 6Interleukin Genetics Reports Third Quarter 2008 Financial Results 7
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Ltd, a private company focused on the development of ... it has entered into a license agreement with the ... worldwide rights to develop and commercialise several novel kinase ... the CNIO,s considerable expertise in drug discovery and comprise ...
... have been officially declared extinct by the International Union for ... of Israel after some 60 years and turns out to ... living frogs. The Hula painted frog was catalogued ... discovered in the Hula Valley of Israel in the early ...
... the clear arguments for controlling parasitic infections, we know ... A good model system for research is provided by ... large intestines of pigs, slowing the animals, growth and ... are available to help keep the parasite in check ...
Cached Biology News:Stopping the worm from turning 2
... DNA Methylation Kit uses a simplified procedure ... methylation analysis. The kit is based on ... between cytosine and sodium bisulfite where cytosine ... Methylation Kits innovative in-column desulphonation reaction eliminates ...
... carbohydrate analysis standard is a lyophilized ... sugar alcohol; molecular weights range from ... provided for use with the Aminex ... kit for column testing or semiquantitative ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 50 mm x 50 ...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
Biology Products: